We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expert Group Says Infocare Drug’s Risk-Benefit Profile Does Not Support Approval
Expert Group Says Infocare Drug’s Risk-Benefit Profile Does Not Support Approval
An FDA advisory committee voted Thursday that Infocare’s NDA for stannsoporfin injection’s overall risk-benefit profile does not support the drug’s approval.